Biopharma Daily Stock Updates - 01/13/21

$XBI $148.57 (-0.52%) 📉


PIPELINE:

$ARQT (-0.66%) - Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis https://investors.arcutis.com/news-releases/news-release-details/arcutis-initiates-pivotal-phase-3-clinical-trials-evaluating


$CYTK (-2.08%) - Cytokinetics Announces First Patient Dosed in Cohort 2 of Redwood-HCM

https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-first-patient-dosed-cohort-2-redwood-hcm


$ELOX (-5.84%) - Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Increased Funding and Support for ELX-02 Global Phase 2 Clinical Trial Program

https://investors.eloxxpharma.com/news-releases/news-release-details/eloxx-pharmaceuticals-announces-cystic-fibrosis-foundation-cf-0


$JNCE (+1.81%) - Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors

https://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-announces-initiation-phase-1-innate-study


$RMTI (+5.93%) - Rockwell Medical Announces Dosing of First Patient in Pivotal Triferic® Phase 3 Trial by Partner, Wanbang Biopharmaceuticals, in China

https://ir.rockwellmed.com/news-releases/news-release-details/rockwell-medical-announces-dosing-first-patient-pivotal


$SESN (-7.50%) - Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum™ Accepted for Review by the National Medical Products Administration in China

https://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-and-qilu-pharmaceutical-announce-ind-application


$URGN (-3.59%) - UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer

https://investors.urogen.com/news-releases/news-release-details/urogen-pharma-and-md-anderson-announce-strategic-research


FINANCIAL:

$ADMS (-2.19%) - Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021

https://ir.adamaspharma.com/news-releases/news-release-details/adamas-provides-preliminary-fourth-quarter-and-full-year-2020

$ESPR (-11.13%) - ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program

https://esperion.com/investors-media/press-releases/?request=aHR0cHM6Ly9lc3Blcmlvbi5nY3Mtd2ViLmNvbS8vbmV3cy1yZWxlYXNlcy9uZXdzLXJlbGVhc2UtZGV0YWlscy9lc3Blcmlvbi1yZXBvcnRzLXByZWxpbWluYXJ5LWZvdXJ0aC1xdWFydGVyLTIwMjAtZmluYW5jaWFs


$SIGA (-2.15%) - SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®

https://investor.siga.com/news-releases/news-release-details/siga-announces-public-health-agency-canada-contract-award



0 comments

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon